Increased monocyte expression of sialoadhesin during acute cellular rejection and other enteritides after intestine transplantation in children.
Chethan Ashokkumar, Anna Gabriellan, Mylarappa Ningappa...
https://pubmed.ncbi.nlm.nih.gov/22249367/Actively Recruiting
Led by University of Pittsburgh · Updated on 2026-08-10
1200
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying biomarkers expressed in biological tissues of solid organ and bone marrow transplant recipients to better understand the effects of drugs used to treat rejection and the processes that lead to rejection or rejection-free outcomes. This observational study collects data to improve knowledge on immunosuppression and allograft function after transplantation. Participants undergo regular monitoring of drug levels and lab tests during hospital admissions or outpatient visits. Blood samples may be collected up to seven times within the first year after transplant and less often afterward, with total blood volume adjusted for patient size and age. Saliva, urine, feces, and bile samples may also be collected up to four times. Additionally, leftover biopsy tissue from routine care or surgery may be analyzed. Cellular responses from blood samples are evaluated through various stimulations to measure inflammatory and immune markers. Throughout the study, participants provide samples indefinitely to allow ongoing assessment of biomarker stability alongside clinical drug levels. Researchers measure rejection severity at 90 days post-transplant and monitor immunosuppression thresholds annually. The study includes detailed laboratory and cellular analyses to track changes over time. Participation may last for many years, depending on ongoing sample collection and monitoring needs.
CONDITIONS
Biomarkers in Transplant Recipients to Improve Outcomes
M
Morgan L Paul, BSN
D
Daniel Pieratt, MPA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Pittsburgh
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Indefinite
Participants provide blood samples up to seven times in the first year and less frequently afterward, along with possible saliva, urine, feces, and bile samples. Leftover biopsy tissue from routine care may also be collected for analysis.
Periodic clinical visits and sample collections as part of routine care
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Chethan Ashokkumar, Anna Gabriellan, Mylarappa Ningappa...
https://pubmed.ncbi.nlm.nih.gov/22249367/Chethan Ashokkumar, Qing Sun, Mylarappa Ningappa...
https://pubmed.ncbi.nlm.nih.gov/25531894/University of Pittsburgh
Lead Sponsor